Signal Genetics Inc. (Nasdaq: SGNL) signed a Master Service Agreement with a leading pharmaceutical to conduct multiple clinical trials using Signal's MyPRS(R) genetic test to develop treatments for patients with multiple myeloma. The stock price surged 89 cents to $2.37.